Company intelligence / Profile preview

Arges Biolab

Seoul, Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

Arges Biolab is a South Korean biotechnology company specializing in the development of next-generation adeno-associated virus (AAV) gene therapies. The company utilizes its proprietary AAV-Arges platform to engineer optimized capsids with enhanced tissue specificity and reduced immunogenicity. Their current pipeline focuses on high-unmet-need areas including ophthalmology and central nervous system disorders, with a lead program targeting wet age-related macular degeneration. Arges Biolab aims to overcome the limitations of existing viral vectors to provide safer and more effective genetic medicines.

Therapeutic areas: NeurologyOphthalmology
Modalities: Gene therapyAdeno-associated virus vector
Industry: Biotech

Beyond the preview

Go deeper on Arges Biolab.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Arges Biolab.

Explore the full profile